Who
Samir Rashmikant Patel
Director
Company insider
Files Form 4 as: Director and 10% owner, Akari Therapeutics; Director, CytoDyn.
In numbers
- Trades disclosed
- 56
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 17 Apr 2020
- Last trade
- 5 Oct 2026
- Last filed
- 16 Oct 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Oct 2026filed 16 Oct 2026 | AKTX Akari TherapeuticsBiotechnology | SEC FORM 4 Code A | $18K2,236 at $7.90 | filing |
| 18 Aug 2026filed 16 Oct 2026 | AKTX Akari TherapeuticsBiotechnology | SEC FORM 4 Code A | $50K6,300 at $7.90 | filing |
| 18 Aug 2026filed 16 Oct 2026 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 18 Aug 2026filed 16 Oct 2026 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 7 Jul 2026filed 17 Jul 2026 | AKTX Akari TherapeuticsBiotechnology | SEC FORM 4 Code M | $9,6721,209 at $8.00 | filing |
| 7 Jul 2026filed 17 Jul 2026 | AKTX Akari TherapeuticsBiotechnology | SEC FORM 4 Code M | $615,466 at $0.0004 | filing |
| 7 Jul 2026filed 17 Jul 2026 | AKTX Akari TherapeuticsBiotechnology | SEC FORM 4 Code M | $25,799 at $0.0004 | filing |
| 7 Jul 2026filed 17 Jul 2026 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | $39K1,209 at $32.00 | filing |
| 7 Jul 2026filed 17 Jul 2026 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | $250K15,466 at $16.16 | filing |
| 7 Jul 2026filed 17 Jul 2026 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | $94K5,799 at $16.16 | filing |
| 7 Jul 2026filed 17 Jul 2026 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | $39K1,209 at $32.00 | filing |
| 7 Jul 2026filed 17 Jul 2026 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | $250K15,466 at $16.16 | filing |
| 7 Jul 2026filed 17 Jul 2026 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | $94K5,799 at $16.16 | filing |
| 7 Jul 2026filed 17 Jul 2026 | AKTX Akari TherapeuticsBiotechnology | SEC FORM 4 Code M | $9,6721,209 at $8.00 | filing |
| 7 Jul 2026filed 17 Jul 2026 | AKTX Akari TherapeuticsBiotechnology | SEC FORM 4 Code M | —15,466 at $0.00 | filing |
| 7 Jul 2026filed 17 Jul 2026 | AKTX Akari TherapeuticsBiotechnology | SEC FORM 4 Code M | —5,799 at $0.00 | filing |
| 16 Dec 2025filed 18 Dec 2025 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | —618,658 | filing |
| 16 Dec 2025filed 18 Dec 2025 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | $247K618,658 at $0.40 | filing |
| 16 Dec 2025filed 18 Dec 2025 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | —231,997 | filing |
| 16 Dec 2025filed 18 Dec 2025 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | $93K231,997 at $0.40 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.